MARIMED INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MARIMED INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $50.90M | Mar 23, 2021 |
| FY2020 | Dec 31, 2019 | $45.60M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $11.85M | Apr 1, 2020 |
| FY2017 | Dec 31, 2017 | $6.07M | Apr 2, 2018 |
| FY2017 | Dec 31, 2016 | $3.56M | Apr 2, 2018 |
| FY2016 | Dec 31, 2015 | $1.27M | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $88.4K | Sep 27, 2016 |
| FY2014 | Dec 31, 2013 | $904 | Jun 9, 2015 |
| FY2013 | Dec 31, 2012 | $785 | Apr 4, 2014 |
| FY2012 | Dec 31, 2011 | $125.6K | Mar 28, 2013 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $159.83M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $157.71M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $148.60M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $134.01M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $121.46M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $50.90M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $45.60M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $11.85M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $6.07M | Apr 16, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $125.6K | Apr 12, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $57.88M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $62.61M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $65.92M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $63.96M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $66.26M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $31.32M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $18.70M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $7.81M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $3.88M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $1.95M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.48M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($12.47M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($16.03M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $13.47M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $7.23M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $2.14M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($81.18M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($13.60M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | ($1.19M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($198.9K) | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.82M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $2.61M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $14.39M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $20.37M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $26.86M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $14.53M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($41.53M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($5.36M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $127.7K | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $775.3K | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2015 | $93.1K | Apr 17, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $770.5K | Apr 17, 2017 |
| FY2016 | Dec 31, 2015 | $567.9K | Apr 17, 2017 |
| FY2015 | Dec 31, 2014 | $302.3K | Sep 27, 2016 |
| FY2014 | Dec 31, 2013 | $122.1K | Jun 9, 2015 |
| FY2013 | Dec 31, 2012 | $184.4K | Apr 4, 2014 |
| FY2012 | Dec 31, 2011 | $188.5K | Mar 28, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.70M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $6.79M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $7.91M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $7.31M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $35.86M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $3.38M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($24.14M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($2.91M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $1.76M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($197.9K) | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.17M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $11.96M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $20.13M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $12.14M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $17.87M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $4.69M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $9.67M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $8.92M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $20.98M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $3.36M | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $202.57M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $206.99M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $196.12M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $152.20M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $123.21M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $76.45M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $61.57M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $82.96M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $32.20M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $8.56M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.83M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $129.44M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $107.21M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $57.17M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $49.18M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $53.62M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $55.24M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $21.20M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $21.19M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $9.11M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | ($551.4K) | Apr 17, 2017 |
| FY2016 | Dec 31, 2015 | ($1.93M) | Apr 17, 2017 |
| FY2016 | Dec 31, 2014 | ($1.93M) | Apr 17, 2017 |
| FY2015 | Dec 31, 2013 | ($1.01M) | Sep 27, 2016 |
| FY2013 | Dec 31, 2012 | ($513.8K) | Apr 4, 2014 |
| FY2013 | Dec 31, 2011 | ($158.7K) | Apr 4, 2014 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.00M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $15.81M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $11.99M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $8.08M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $2.07M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $2.07M | Mar 3, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($127.93M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($113.45M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($99.96M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($83.92M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($97.39M) | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | ($104.62M) | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | ($106.76M) | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | ($25.58M) | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | ($11.97M) | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | ($10.78M) | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $7.28M | Mar 6, 2025 |
| FY2024 | Dec 31, 2023 | $14.65M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $9.74M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $29.68M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | $3.00M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | $738.7K | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | $4.10M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | $1.29M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | $569.4K | Apr 2, 2018 |
| FY2017 | Dec 31, 2015 | $160.9K | Apr 2, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.04M | Mar 12, 2026 |
| FY2024 | Dec 31, 2024 | $78.19M | Mar 6, 2025 |
| FY2020 | Dec 31, 2020 | $36.71M | Mar 23, 2021 |
| FY2019 | Dec 31, 2019 | $36.28M | Apr 1, 2020 |
| FY2018 | Dec 31, 2018 | $14.97M | Apr 16, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 23, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 23, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 396.91M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 381.48M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 375.13M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 341.47M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 334.03M | Mar 3, 2023 |
| FY2021 | Dec 31, 2020 | 314.42M | Mar 16, 2022 |
| FY2020 | Dec 31, 2019 | 228.41M | Mar 23, 2021 |
| FY2019 | Dec 31, 2018 | 211.01M | Apr 1, 2020 |
| FY2018 | Dec 31, 2017 | 176.85M | Apr 16, 2019 |
| FY2017 | Dec 31, 2016 | 64.07M | Apr 2, 2018 |